Technology | December 23, 2009

Drug Reference Application Available for Android

December 24, 2009 – A clinical reference and pharmaceutical database application was released this week for the Google Android personal digital assistant (PDA) device.

Lexi-Comp ON-HAND for Android features Lexi-Drugs, a comprehensive pharmacology database. Users can create and store personalized user notes within each monograph, as well as diagnose, find treatment options, and identify drug interactions in seconds. Databases stored on the memory card allow for quick access to the equivalent of more than 65,000 printed pages of the most updated clinical information available on a smartphone.

The application allows users to view tables, charts, appendices, and images as they are seen in Lexi-Comp’s handbooks and Internet platforms. Also, downloading and updating the software is now done over the air, with no cords or syncing required.

With Lexi-Comp ON-HAND software, clinicians can link to FDA warnings, PubMed, and additional resources directly from their phone. Additional licensed resources include “Harrison’s Practice,” “The 5-Minute Clinical Consultant,” and “Stedman’s Medical Dictionary” for the “Health Professions and Nursing.”

This platform expands Lexi-Comp’s handheld solution, which also includes compatibility with the iPod touch, smartphones including iPhone, BlackBerry and Windows Mobile, as well as Palm, Pocket PC devices, and any device with Web browser capabilities.

For more information: www.lexi.com/pda/google-android

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init